PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Madan H. Jagasia, MBBS, MS, MMHC - Innovative Therapies in Post-Transplant GVHD: Personal Insights From the Patient CaseBook
Go online to PeerView.com/XYM860 to view the entire program with slides. This activity utilizes a “CaseBook” format, offering learners a collection of patient case scenarios from the experts’ personal repertoire paired with analyses of how the treatment landscape in acute and chronic graft-versus-host disease (GVHD) is evolving. Hematology-oncology and bone marrow transplant professionals take a deep dive into the underlying immunology of GVHD and the latest evidence with innovative therapeutics while also obtaining expert perspectives on the practical application of these advancements as prophylaxis or for treatment of acute and chronic, steroid–nonresponsive, and previously untreated GVHD. Upon completion of this activity, participants should be better able to: Describe the underlying immunology of post-transplant GVHD, and the rationale for and mechanisms of novel therapies in the management of GVHD, Discuss the latest evidence on novel therapies, including JAK 1/2 inhibitors, BTK inhibitors, and T-cell costimulation modulators, for prophylaxis or treatment of acute or chronic, steroid-naïve or steroid-refractory GVHD in the HSCT setting, Apply the most optimal evidence-based strategies, including enrollment in clinical trials, for post-transplant GVHD care based on individual patient and disease characteristics.